CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 305.92 Million JPY | 34.76% |
| 2022 | 227.02 Million JPY | 37.14% |
| 2021 | 165.54 Million JPY | 25.1% |
| 2020 | 132.32 Million JPY | -19.79% |
| 2019 | 164.97 Million JPY | 33.56% |
| 2018 | 123.52 Million JPY | 61.61% |
| 2017 | 76.43 Million JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 252.1 Million JPY | 8.73% |
| 2024 Q2 | 231.87 Million JPY | -7.93% |
| 2024 Q1 | 251.83 Million JPY | -17.68% |
| 2023 Q4 | 305.92 Million JPY | 11.94% |
| 2023 FY | 305.92 Million JPY | 34.76% |
| 2023 Q3 | 273.29 Million JPY | 16.54% |
| 2023 Q2 | 234.5 Million JPY | 1.18% |
| 2023 Q1 | 231.77 Million JPY | 2.09% |
| 2022 Q2 | 194.85 Million JPY | 19.03% |
| 2022 Q1 | 163.7 Million JPY | -1.11% |
| 2022 Q4 | 227.02 Million JPY | 3.4% |
| 2022 FY | 227.02 Million JPY | 37.14% |
| 2022 Q3 | 219.55 Million JPY | 12.68% |
| 2021 Q1 | 138.16 Million JPY | 4.41% |
| 2021 Q2 | 168.48 Million JPY | 21.94% |
| 2021 Q3 | 172.66 Million JPY | 2.48% |
| 2021 Q4 | 165.54 Million JPY | -4.12% |
| 2021 FY | 165.54 Million JPY | 25.1% |
| 2020 FY | 132.32 Million JPY | -19.79% |
| 2020 Q1 | 165.02 Million JPY | 0.03% |
| 2020 Q4 | 132.32 Million JPY | -18.24% |
| 2020 Q3 | 161.85 Million JPY | -5.31% |
| 2020 Q2 | 170.92 Million JPY | 3.58% |
| 2019 Q3 | 150.55 Million JPY | 0.0% |
| 2019 Q4 | 164.97 Million JPY | 9.58% |
| 2019 FY | 164.97 Million JPY | 33.56% |
| 2018 FY | 123.52 Million JPY | 61.61% |
| 2017 FY | 76.43 Million JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | 55.209% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | -1606.314% |
| GNI Group Ltd. | 2.33 Billion JPY | 86.874% |
| Linical Co., Ltd. | - JPY | -Infinity% |
| Trans Genic Inc. | 2.22 Billion JPY | 86.267% |
| MEDINET Co., Ltd. | 67.48 Million JPY | -353.35% |
| Soiken Holdings Inc. | 1.12 Billion JPY | 72.706% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | -195.483% |
| AnGes, Inc. | 1.61 Billion JPY | 81.067% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | -313.418% |
| Nxera Pharma Co., Ltd. | 2.9 Billion JPY | 89.462% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | 4.967% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | -166163.587% |
| Carna Biosciences, Inc. | 140.14 Million JPY | -118.3% |
| CanBas Co., Ltd. | 728 Thousand JPY | -41922.665% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | -248.184% |
| RaQualia Pharma Inc. | 147.93 Million JPY | -106.791% |
| Chiome Bioscience Inc. | 64.1 Million JPY | -377.21% |
| Kidswell Bio Corporation | 875.65 Million JPY | 65.063% |
| PeptiDream Inc. | 2.4 Billion JPY | 87.275% |
| Oncolys BioPharma Inc. | 5.34 Million JPY | -5626.788% |
| Ribomic Inc. | 2.27 Million JPY | -13353.166% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | - JPY | -Infinity% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | -30592499900.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | -749.792% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | 29 Million JPY | -954.914% |
| FunPep Company Limited | 25.54 Million JPY | -1097.78% |
| Kringle Pharma, Inc. | 364.05 Million JPY | 15.968% |
| Stella Pharma Corporation | 1.11 Billion JPY | 72.594% |
| TMS Co., Ltd. | 50.02 Million JPY | -511.544% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | -1363.686% |
| Cuorips Inc. | 1.04 Million JPY | -29231.256% |
| K Pharma,Inc. | 10.79 Million JPY | -2734.213% |
| Takara Bio Inc. | 11.85 Billion JPY | 97.418% |
| ReproCELL Incorporated | 248.14 Million JPY | -23.287% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | 32.105% |
| StemCell Institute Inc. | 42.26 Million JPY | -623.877% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | -33.846% |
| CellSeed Inc. | 46.19 Million JPY | -562.304% |